Vicarious Surgical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Vicarious SurgicalDer Gewinn des Unternehmens wird voraussichtlich um 4.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 62.3% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 0.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -116.9% betragen.

Wichtige Informationen

-4.1%

Wachstumsrate der Gewinne

0.6%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.7%
Wachstumsrate der Einnahmen	62.3%
Zukünftige Eigenkapitalrendite	-116.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Mar 05

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Nov 24

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

Aug 24

Gewinn- und Umsatzwachstumsprognosen

NYSE:RBOT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-79	N/A	N/A	3
12/31/2025	N/A	-75	N/A	N/A	3
12/31/2024	N/A	-67	N/A	N/A	3
3/31/2024	N/A	-61	-60	-58	N/A
12/31/2023	N/A	-71	-64	-62	N/A
9/30/2023	N/A	-69	-71	-69	N/A
6/30/2023	N/A	-78	-68	-66	N/A
3/31/2023	N/A	-64	-69	-65	N/A
12/31/2022	N/A	5	-67	-61	N/A
9/30/2022	N/A	38	-58	-53	N/A
6/30/2022	N/A	18	-57	-52	N/A
3/31/2022	N/A	13	-47	-44	N/A
12/31/2021	N/A	-35	-35	-33	N/A
9/30/2021	N/A	-61	-28	-27	N/A
6/30/2021	N/A	-19	-17	-16	N/A
3/31/2021	N/A	-15	-14	-14	N/A
12/31/2020	N/A	-13	-12	-12	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RBOT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RBOT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RBOT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RBOT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: RBOT wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RBOT wird voraussichtlich in 3 Jahren unrentabel sein.

Vicarious Surgical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 84% to US$1.13

Price target decreased by 21% to US$7.75

Price target decreased to US$11.80

Recent updates

Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024

Vicarious Surgical Inc. to Report Q1, 2024 Results on Apr 29, 2024

New major risk - Revenue and earnings growth

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Vicarious Surgical Inc. to Report Q4, 2023 Results on Mar 04, 2024

Vicarious Surgical Inc. Announces Management Changes

Vicarious Surgical Inc. Announces Appointment of Randy Clark as President Effective, January 29, 2024

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Price target decreased by 84% to US$1.13

Vicarious Surgical Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Market cap size

Vicarious Surgical Receives Continued Listing Standard Notice From NYSE

Vicarious Surgical Receives Continued Listing Standard Notice From NYSE

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

New minor risk - Share price stability

Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn Situation

Vicarious Surgical Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Insider selling

Co-Founder recently sold US$54k worth of stock

Vicarious Surgical: Cash Burn Adds To Downside Risk

Co-Founder notifies of intention to sell stock

Vicarious Surgical Inc. Announces Promotion of John Mazzola to Chief Operating Officer

Insider recently bought US$153k worth of stock

Investor sentiment deteriorates as stock falls 21%

Insider recently bought US$139k worth of stock

Insider recently bought US$78k worth of stock

Co-Founder recently sold US$65k worth of stock

Co-Founder notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 21% to US$7.75

Insider recently bought US$241k worth of stock

Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02

Investor sentiment improves as stock rises 17%

Vicarious Surgical Inc. to Report Q4, 2022 Results on Feb 13, 2023

Vicarious Surgical Inc. Announces Changes to Board of Directors

Investor sentiment improved over the past week

Vicarious Surgical Completes Public Demonstration of Beta 2 Surgical Robotic System

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Co-Founder recently sold US$74k worth of stock

High number of new and inexperienced directors

Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03

Investor sentiment improved over the past week

Vicarious Surgical Inc. to Report Q3, 2022 Results on Nov 07, 2022

CFO & Treasurer notifies of intention to sell stock

Vicarious Surgical Inc. Announces Changes to Board of Directors

Independent Director recently sold US$54k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Independent Director recently sold US$87k worth of stock

Vicarious Surgical Non-GAAP EPS of -$0.16 misses by $0.02

Vicarious Surgical Inc. to Report Q2, 2022 Results on Aug 08, 2022

Investor sentiment improved over the past week

Vectoring In On Vicarious Surgical Inc.

Investor sentiment improved over the past week

Independent Director recently sold US$119k worth of stock

Investor sentiment improved over the past week

Independent Director recently sold US$169k worth of stock

High number of new and inexperienced directors

Vicarious Surgical Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$11.80

Vicarious Surgical Inc. to Report Q1, 2022 Results on May 09, 2022

Vicarious Surgical Inc. to Report Q4, 2021 Results on Mar 03, 2022

Vicarious Surgical: Developing Minimally Invasive VR Surgical System

No independent directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken